Rising obesity rates in the US highlight the growing need for effective weight-management options. Glucagon-like peptide-1 (GLP-1) agonists, originally developed for type 2 diabetes mellitus, have become increasingly popular for weight management due to their appetite-reducing and satiety-enhancing effects. To evaluate self-reported effectiveness, perceptions of safety, and barriers associated with GLP-1 agonists among US adults. An online survey was distributed via Prolific in May 2024. A total of 1955 usable observations were categorized into four groups: Currently Taking ( n = 495), Previously Taken ( n = 468), Planning to Take ( n = 492), and Neither Taken nor Planning ( n = 500). Interval, binary logistic, and ordered probit models were estimated. In the Currently Taking group, self-reported weight loss averaged 16.44 lb at ≤ 6 months, 29.83 lb at 6–12 months, and 36.09 lb at > 1 year; in the Previously Taken group, the corresponding means were 14.93 lb, 24.70 lb, and 31.81 lb. Financial constraints, side effects (notably nausea and gastrointestinal issues), and insufficient insurance coverage were the most commonly reported barriers. Respondents generally perceived GLP-1 agonists as safe for short- and long-term use, with stronger positive perceptions among those with higher education and greater self-reported knowledge of the medications. These self-reported patient experiences suggest that improving affordability and insurance coverage of GLP-1 agonists could support more effective real-world weight management, while reinforcing the need for longitudinal clinical research.
Silwal et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: